{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:04:02Z","timestamp":1792728242651,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s15010-020-01539-9","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T09:03:01Z","timestamp":1603098181000},"page":"549-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Ceftazidime\/avibactam and ceftolozane\/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-9995","authenticated-orcid":false,"given":"Marianna","family":"Meschiari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Franconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Bacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Cuomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bedini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"key":"1539_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"1539_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/cid\/cix014","volume":"65","author":"JM Munita","year":"2017","unstructured":"Munita JM, Aitken SL, Miller WR, Perez F, Rosa R, Shimose LA, et al. Multicenter evaluation of ceftolozane\/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2017;65:158\u201361.","journal-title":"Clin Infect Dis"},{"key":"1539_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jgar.2018.07.010","volume":"15","author":"O Rodr\u00edguez-N\u00fa\u00f1ez","year":"2018","unstructured":"Rodr\u00edguez-N\u00fa\u00f1ez O, Ripa M, Morata L, de la Calle C, Cardozo C, Feh\u00e9r C, Pellic\u00e9 M, Valc\u00e1rcel A, Puerta-Alcalde P, Marco F, Garc\u00eda-Vidal C, del R\u00edo A, Soriano A. J Mart\u00ednez-Mart\u00ednez Evaluation of ceftazidime\/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. J Glob Antimicrob Resist. 2018;15:136\u20139.","journal-title":"J Glob Antimicrob Resist"},{"key":"1539_CR4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","volume":"53","author":"M Bassetti","year":"2019","unstructured":"Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, Tascini C, et al. Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents. 2019;53:408\u201315.","journal-title":"Int J Antimicrob Agents"},{"key":"1539_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ijantimicag.2017.11.003","volume":"51","author":"B Dietl","year":"2018","unstructured":"Dietl B, S\u00e1nchez I, Arcenillas P, Cuchi E, G\u00f3mez L, Gonz\u00e1lez de Molina FJ, Boix-Palop L, Nicol\u00e1s J, Calbo E. Ceftolozane\/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes. Int J Antimicrobial Agents. 2018;51:498\u20135027.","journal-title":"Int J Antimicrobial Agents"},{"key":"1539_CR6","first-page":"00451","volume":"31","author":"Antonella Frattaria","year":"2018","unstructured":"Frattaria Antonella, Savini Vincenzo, Polilli Ennio, Cibelli Donatella, Talamazzi Silvia, Bosco Donatella, Consorte Augusta, Fazii Paolo, Parruti Giustino. Ceftolozane-tazobactam and Fosfomycin for rescue treatment of otogenous meningitis caused by XDR Pseudomonas aeruginosa: case report and review of the literature. ID Cases. 2018;31:00451.","journal-title":"ID Cases"},{"key":"1539_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.11.005","volume":"49","author":"M Xipell","year":"2017","unstructured":"Xipell M, Bodro M, Marco F, Losno RA, Cardozo C, Soriano A. Clinical experience with ceftazidime\/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2017;49:259\u201368.","journal-title":"Int J Antimicrob Agents"},{"key":"1539_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/cid\/ciw861","volume":"64","author":"Allan R Tunkel","year":"2017","unstructured":"Tunkel Allan R, Hasbun Rodrigo, Bhimraj Adarsh, Byers Karin, Kaplan Sheldon L, Michael Scheld W, van de Beek Diederik, Bleck Thomas P, Garton Hugh JL, Zunt Joseph R. Infectious Diseases Society of America\u2019s Clinical Practice Guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. 2017;64:34\u201365.","journal-title":"Clin Infect Dis"},{"key":"1539_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.wneu.2018.08.138","volume":"120","author":"M Karvouniaris","year":"2018","unstructured":"Karvouniaris M, Brotis AG, Tsiamalou P, et al. The role of intraventricular antibiotics in the treatment of nosocomial ventriculitis\/meningitis from gram-negative pathogens: a systematic review and meta-analysis. World Neurosurg. 2018;120:637\u201350.","journal-title":"World Neurosurg"},{"key":"1539_CR10","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/civ097","volume":"60","author":"J Solomkin","year":"2015","unstructured":"Solomkin J, Hershberger E, Miller B, et al. Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462\u201371.","journal-title":"Clin Infect Dis"},{"key":"1539_CR11","doi-asserted-by":"publisher","first-page":"02187-18","DOI":"10.1128\/AAC.02187-18","volume":"63","author":"S Das","year":"2019","unstructured":"Das S, Li J, Riccobene T, Carrothers TJ, Newell P, Melnick D, Critchley IA, Stone GG, Nichols WW. Dose selection and validation for\u00a0ceftazidime-avibactam\u00a0in adults with complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia. Antimicrob Agents Chemother. 2019;63:02187-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1539_CR12","unstructured":"Roberts JA. Ceftolozane-tazobactam pharmacokinetics in infected critically ill patients with an indwelling External Ventricular Drain, PhD. ClinicalTrials.gov identifier (NCT number): NCT03309657. Australia: Royal Brisbane and Women\u2019s Hospital, University of Brisbane; 2018. Accessed 15 Feb 2018."},{"key":"1539_CR13","doi-asserted-by":"publisher","first-page":"e01008","DOI":"10.1128\/AAC.01008-17","volume":"61","author":"B Davido","year":"2017","unstructured":"Davido B, Fellous L, Lawrence C, Maxime V, Rottman M, Dinh A. Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61:e01008\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"1539_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.4103\/0974-8237.193264","volume":"7","author":"SK Meher","year":"2016","unstructured":"Meher SK, Jain H, Tripathy LN, Basu S. Chronic\u00a0Pseudomonas aeruginosa\u00a0cervical osteomyelitis. J Craniovertebr Junction Spine. 2016;7:276\u20138. https:\/\/doi.org\/10.4103\/0974-8237.193264.","journal-title":"J Craniovertebr Junction Spine"},{"key":"1539_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00228-015-1865-4","volume":"71","author":"A Ordooei Javan","year":"2015","unstructured":"Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2015;71:801\u201310. https:\/\/doi.org\/10.1007\/s00228-015-1865-4(Epub 2015 May 27).","journal-title":"Eur J Clin Pharmacol"},{"key":"1539_CR16","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1128\/aac.00997-16","volume":"60","author":"C Lu","year":"2016","unstructured":"Lu C, Zhang Y, Chen M, Zhong P, Chen Y, Yu J, Wu X, Wu J, Zhang J. Population pharmacokinetics and dosing regimen optimization of meropenem in cerebrospinal fluid and plasma in patients with meningitis after neurosurgery. Antimicrob Agents Chemother. 2016;60:6619\u201325. https:\/\/doi.org\/10.1128\/aac.00997-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"1539_CR17","doi-asserted-by":"publisher","first-page":"e00794-17","DOI":"10.1128\/aac.00794-17","volume":"61","author":"P Cojutti","year":"2017","unstructured":"Cojutti P, Sartor A, Righi E, Scarparo C, Bassetti M, Pea F. Population pharmacokinetics of high-dose continuous- infusion meropenem and considerations for use in the treatment of infections due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61:e00794-17. https:\/\/doi.org\/10.1128\/aac.00794-17.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-020-01539-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-020-01539-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-020-01539-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:46:36Z","timestamp":1744166796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-020-01539-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1539"],"URL":"https:\/\/doi.org\/10.1007\/s15010-020-01539-9","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]},"assertion":[{"value":"24 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was reviewed and approved by the University of Modena and Reggio Emilia local institutional Ethical Committee (Comitato Etico Provinciale di Modena). The study was conducted in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All involved persons gave their informed verbal witnessed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent for publication was obtained from all participants to the study. Data were published anonymously.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}